Migdal Insurance & Financial Holdings Ltd. Nektar Therapeutics Transaction History

Migdal Insurance & Financial Holdings Ltd.

$7.12 Billion
Q1 2025

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $37,428 - $69,679	-1,230 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$46.46 - $68.49 $35,356 - $52,120	761 Added 162.26%	1,230 $75,000
Q2 2018 Aug 01, 2018	BUY	$46.25 - $104.45 $20,997 - $47,420	454 Added 3026.67%	469 $23,000
Q1 2018 May 02, 2018	BUY	$57.4 - $108.44 $861 - $1,626	15 New	15 $2,000

Others Institutions Holding NKTR

# of Institutions

168

Shares Held

123M

Call Options Held

1.18M

Put Options Held

64.6K

Black Rock Inc. New York, NY

15.2M
Shares

$10.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

12.3M
Shares

$8.49 Million
0.0% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

7.79M
Shares

$5.37 Million
0.24% of portfolio
Acadian Asset Management LLC Boston, MA

7.3M
Shares

$5.04 Million
0.01% of portfolio
Eventide Asset Management, LLC Boston, MA

6.65M
Shares

$4.59 Million
0.1% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $129M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account